-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Mju0Rvscf+T3/065wPT3E76oXtmrLW3RDevNqi/XitkZJh9VBJ6/BhhfSk+Y5a/z hjZ7NibCFnIwdQKGRI+qHQ== 0000950155-04-000073.txt : 20040323 0000950155-04-000073.hdr.sgml : 20040323 20040323134956 ACCESSION NUMBER: 0000950155-04-000073 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040323 GROUP MEMBERS: INGALLS & SNYDER VALUE PARTNERS, L.P. GROUP MEMBERS: ROBERT L. GIPSON GROUP MEMBERS: THOMAS O. BOUCHER, JR. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-07548 FILM NUMBER: 04684633 BUSINESS ADDRESS: STREET 1: 137 NEWBURY STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174250200 MAIL ADDRESS: STREET 1: 137 NEWBURY STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INGALLS & SNYDER LLC CENTRAL INDEX KEY: 0001041885 IRS NUMBER: 135156620 STATE OF INCORPORATION: NY FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 61 BROADWAY STREET 2: C/O INGALLS & SNYDER CITY: NEW YORK STATE: NY ZIP: 100006 BUSINESS PHONE: 2122697812 MAIL ADDRESS: STREET 1: 61 BROADWAY CITY: NEW YORK STATE: NY ZIP: 100006 SC 13D/A 1 e834764sch13da.txt SCHEDULE 13D AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5) BOSTON LIFE SCIENCES, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK - -------------------------------------------------------------------------------- (Title of Class of Securities) 100843408 ---------------------------------------------------------- (CUSIP Number) March 22, 2004 ---------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Thomas O. Boucher, Jr. Ingalls & Snyder, LLC 61 Broadway New York, New York 10006 212-269-7800 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [x]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). This Amendment No. 5 amends the statement on Schedule 13D, dated September 29, 2003, as amended, relating to Boston Life Sciences, Inc. (the "Company") as follows: ITEM 4. PURPOSE OF THE TRANSACTION The following is added after the last paragraph of Item 4: On March 22, 2004, Mr. Gipson sent to the Company a demand for inspection of books and records of the Company pursuant to Section 220 of the Delaware General Corporation Law. The purpose of the demand is to investigate possible mismanagement, waste of corporate assets, breach of fiduciary duty, improper influence or conduct and lack of due care by the directors of the Company. Since applicable Delaware case law restricts a stockholder's ability to utilize the Section 220 inspection procedure to investigate wrongdoing while related derivative litigation is pending, the Reporting Persons requested that the Delaware Court of Chancery dismiss the Financing Transaction Complaint without prejudice to the Reporting Persons' ability to refile such a complaint at a later time. The Court granted the Reporting Persons' request. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct. Date: March 23, 2004 INGALLS & SNYDER, LLC By: /s/ THOMAS O. BOUCHER, JR. ------------------------------------- Thomas O. Boucher, Jr. Managing Director INGALLS & SNYDER VALUE PARTNERS, L.P. By: /s/ THOMAS O. BOUCHER, JR. ------------------------------------- Thomas O. Boucher, Jr. General Partner /s/ THOMAS O. BOUCHER, JR. - ----------------------------------------- Thomas O. Boucher, Jr. /s/ ROBERT L. GIPSON - ----------------------------------------- Robert L. Gipson -----END PRIVACY-ENHANCED MESSAGE-----